Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VD vs VTD induction before autologous stem cell transplantation in newly diagnosed multiple myeloma
2007-005204-40Phase 3Active
- Sponsor
- Inter-Groupe Francophone du Myélome
- Start
- Dec 2007
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of bortezomib in multiple myeloma (MM) (2 arms), sponsored by Inter-Groupe Francophone du Myélome. Primary endpoint: Complete remission rate after induction. Started Dec 2007; status: active.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2007-005204-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005204-40.